Daniel Blackman
Professor of Interventional Cardiology at the University of Leeds and Consultant Interventional Cardiologist at Leeds Teaching Hospitals NHS Trust, an internationally recognised expert in transcatheter aortic valve implantation (TAVI) and structural heart disease.
1
APPEARANCES
1
PODCASTS
Aug 27, 2026
Ole de BackerHOST
So then may I ask, what do you see as one of the most important latest evidences in this field on coronary revascularization in patients undergoing TAVI?
Daniel BlackmanGUEST
Well, Ole, as you said, you know, we know about 50% of patients undergoing TAVI have significant coronary artery disease, so it's a question we've been looking for answers for since we started doing this procedure really.
Daniel BlackmanGUEST
Um, and what we've seen recently is the PROTAVI Trial, uh, which as you know, uh, randomized patients of 466 patients to have either PCI prior to TAVI or PCI deferred, uh, and undertaken only afterwards if clinically indicated.
Daniel BlackmanGUEST
The primary endpoint, I think importantly excluded revascularization and looked at the hard real clinical endpoints, death-
Daniel BlackmanGUEST
Um, but, you know, it's fair to say that in NOTION-3 it wasn't just urgent revascularization.